ICDR arbitrator decides multibillion life sciences dispute
A sole arbitrator at the ICDR has ruled in favour of Daiichi Sankyo in a dispute potentially worth billions of dollars over rights to technology the Japanese drugmaker is using in cancer medicines.
To read more
Subscribe to Global Arbitration Review
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the Global Arbitration Review experts.